{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:51:33Z","timestamp":1793962293338,"version":"4.8.0"},"reference-count":19,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,3,19]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The objective is to evaluate perscriptions of belimumab (BEL), how these have changed over the years and their impact on clinical outcomes in patients with systemic lupus erythematosus (SLE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a retrospective analysis of prospectively collected data. We retrieved demographic and clinical data and concomitant therapies at BEL starting (baseline). Disease activity was assessed at baseline and after 6 and 12 months and organ damage at baseline and at the last visit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 422 patients followed in the Pisa SLE cohort, 102 patients received BEL and were included and 22 (21.6%) were immunosuppressant (IS)-na\u00efve. Lupus Low Disease Activity State (LLDAS) with a glucocorticoid (GC) dosage \u22645\u2009mg\/day (LLDAS5) and remission were achieved by 47% and 38% of patients at 6 months, and by 75% and 66% at 12 months. Comparing IS-na\u00efve patients with those who received BEL after at least one conventional IS, we did not find significant differences in baseline characteristics and in the achievement of LLDAS5 and remission. Despite at baseline we did not observe significant differences in mean GC daily dosage, IS-na\u00efve patients were taking a significantly lower GC daily dose at 6 and 12 months. Interestingly, IS-na\u00efve patients were more common in the most recent years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our data confirm that BEL is effective in controlling disease activity, and in recent years BEL has been considered as an earlier treatment option before other IS. Early introduction of BEL can be at least as effective as a step-up approach and can help to reduce the GC dosage.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003981","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T21:55:12Z","timestamp":1712958912000},"page":"e003981","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0870-8738","authenticated-orcid":false,"given":"Chiara","family":"Tani","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"},{"name":"Department of Medical Biotechnologies, University of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-2562","authenticated-orcid":false,"given":"Dina","family":"Zucchi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"},{"name":"Department of Medical Biotechnologies, University of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6407-6213","authenticated-orcid":false,"given":"Chiara","family":"Cardelli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0657-485X","authenticated-orcid":false,"given":"Elena","family":"Elefante","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Signorini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Schilir\u00f2","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Cascarano","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gualtieri","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya","family":"Valevich","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Puccetti","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Carli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Stagnaro","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"2025090312170044000_10.2.e003981.1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00454-9"},{"key":"2025090312170044000_10.2.e003981.2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653"},{"key":"2025090312170044000_10.2.e003981.3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24901"},{"key":"2025090312170044000_10.2.e003981.4","doi-asserted-by":"crossref","unstructured":"Fanouriakis A , Kostopoulou M , Andersen J , et al . EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2023.","DOI":"10.1136\/ard-2024-225617"},{"key":"2025090312170044000_10.2.e003981.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819"},{"key":"2025090312170044000_10.2.e003981.6","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2025090312170044000_10.2.e003981.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400506"},{"key":"2025090312170044000_10.2.e003981.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"2025090312170044000_10.2.e003981.9","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000234","article-title":"Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort","volume":"5","author":"Tani","year":"2018","journal-title":"Lupus Sci Med"},{"key":"2025090312170044000_10.2.e003981.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1192"},{"key":"2025090312170044000_10.2.e003981.11","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6963-14-469","article-title":"Factors affecting the uptake of new medicines: a systematic literature review","volume":"14","author":"Lubl\u00f3y","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"2025090312170044000_10.2.e003981.12","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6963-12-56","article-title":"Adoption of new drugs by physicians: a survival analysis","volume":"12","author":"Garj\u00f3n","year":"2012","journal-title":"BMC Health Serv Res"},{"key":"2025090312170044000_10.2.e003981.13","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201200186"},{"key":"2025090312170044000_10.2.e003981.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2025090312170044000_10.2.e003981.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.41253"},{"key":"2025090312170044000_10.2.e003981.16","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215732","article-title":"Achieving lupus low-disease activity and remission States under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter","volume":"79","author":"Sbeih","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090312170044000_10.2.e003981.17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074044","article-title":"Clinical response Trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: a real-life, multicentre observational study","volume":"13","author":"Nikoloudaki","year":"2022","journal-title":"Front Immunol"},{"key":"2025090312170044000_10.2.e003981.18","doi-asserted-by":"crossref","unstructured":"Zhao Y , Qi F , Bai J , et al . Real-world efficacy of belimumab in systemic lupus erythematosus: a prospective cohort from a single center in China. Rheumatology 2023. doi:10.1093\/rheumatology\/kead629","DOI":"10.1093\/rheumatology\/kead629"},{"key":"2025090312170044000_10.2.e003981.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205139"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:17:07Z","timestamp":1756927027000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4,12]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/rmdopen-2023-003981"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003981","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}